Patent · US Active

Biparatopic polypeptides antagonizing Wnt signaling in tumor cells

US11952418B2 · kind B2 · utility

1Cited by

1References

3Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Vittoria Zinzalla · Wien, AT
Klaus-Peter Kuenkele · Perchtoldsdorf, AT
Marie-Ange Buyse · Merelbeke, BE
Karen Cromie · Merelbeke, BE
Stephanie Staelens · Wevelgem, BE
Beatrijs Strubbe · Zwijnaarde, BE

Key dates

Filing date	Feb 12, 2020
Grant date	Apr 9, 2024
Priority date	—
Expiry date	Oct 2, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.